Biocept Inc (NASDAQ:BIOC) saw unusually-strong trading volume on Thursday . Approximately 13,526,320 shares changed hands during trading, an increase of 370% from the previous session’s volume of 2,876,126 shares.The stock last traded at $1.58 and had previously closed at $1.20.

Several equities analysts recently issued reports on BIOC shares. ValuEngine upgraded shares of Biocept from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, February 13th.

The company has a current ratio of 2.63, a quick ratio of 2.50 and a debt-to-equity ratio of 0.11. The stock has a market cap of $2.68 million, a PE ratio of -0.07 and a beta of 2.90.

A hedge fund recently raised its stake in Biocept stock. Dimensional Fund Advisors LP boosted its holdings in Biocept Inc (NASDAQ:BIOC) by 180.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 110,500 shares of the medical research company’s stock after purchasing an additional 71,055 shares during the quarter. Dimensional Fund Advisors LP owned about 4.86% of Biocept worth $95,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 14.66% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at

About Biocept (NASDAQ:BIOC)

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Recommended Story: What is Net Asset Value (NAV)?

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.